%0 Journal Article
%T Do Tumor Characteristics and Pre-Transplant Locoregional Therapy Predict Survival after OLT in Patients with Hepatocellular Carcinoma?
%A Mohamed Kohla
%A Richard Shaw
%A Garret Hisatak
%A Robert Osorio
%A Maurizio Bonacini
%J International Journal of Clinical Medicine
%P 25-31
%@ 2158-2882
%D 2013
%I Scientific Research Publishing
%R 10.4236/ijcm.2013.412A1006
%X <p class=\"MsoNormal\">
	<span lang=\"EN-US\" style=\"font-family:Verdana;\">HCC prognosis after OLT is associated
with criteria related to </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">the </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">number and size. However, </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">the </span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">degree of differentiation and efficacy of locoregional therapies may also
influence outcome. </span><span style=\"font-family:Verdana;\">Aim:</span><span style=\"font-family:Verdana;\"> Characterize
patients with and without HCC and compare outcomes according to tumor
characteristics. </span><span style=\"font-family:Verdana;\">Methods:</span></span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">Retrospective query of an electronic
medical record of 328 patients transplanted at California Pacific Medical
Center (CPMC) in 2001-2007. HCC was defined by pre-OLT listing data as well as </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">the </span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">finding of a tumor consistent with HCC
at liver explant. Milan and UCSF criteria were applied to the lesions as
described by pathology upon explant examination. </span><span style=\"font-family:Verdana;\">Results:</span><span style=\"font-family:Verdana;\"> 328 patients were evaluated, with 109 liver malignancies</span></span><span lang=\"EN-US\" style=\"font-family:Verdana;\">, </span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">103 females (26 (25%) HCC) and 225
males (83 (37%) HCC </span><i><span style=\"font-family:Verdana;\">p</span></i></span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">=</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">0.04). HCC patients were older (56</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">7.2 yr) than non HCC patients (51</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">¡À</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">9.2, </span><i><span style=\"font-family:Verdana;\">p</span></i></span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">&lt;</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">0.001). </span><span
%K Tumor Characteristics
%K Locoregional Therapy
%K Hepatolcellular Carcinoma
%K Liver Transplantation
%K OLT
%K Survival
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=41415